Laxmi Dental Q1FY27 Revenue at ₹75 Crore, Up 13.9% YoY
Laxmi Dental reported Q1 FY27 revenue of ₹75 crore, up 13.9% YoY. Gross profit increased 22.1% to ₹58.7 crore, and EBITDA rose 20.6% to ₹14.4 crore. PAT grew 23.8% to ₹10.3 crore. The dental laboratory business grew 23.5% YoY, and Aligner Solutions business grew 28.6% YoY.
The Q1 FY27 results show positive growth and strategic initiatives, which are likely to be viewed favorably by investors, indicating a medium impact on the stock.
The company reported strong revenue growth and improved profitability, driven by robust performance in its key business segments.
Laxmi Dental Limited has announced its Q1 FY27 earnings, reporting the highest-ever quarterly revenue of approximately ₹75 crore, marking a 13.9% year-on-year growth. The company's profitability saw improvement due to a better product mix.
The company is strengthening its on-ground leadership in the U.S. to sustain growth and has established three new support facilities in India to deepen regional presence and enhance market penetration.
Financially, for Q1 FY27, consolidated revenues stood at ₹747.0 million (₹74.7 crore), with a 13.9% YoY increase. Gross profit grew by 22.1% to ₹587.0 million (₹58.7 crore), and EBITDA increased by 20.6% to ₹143.6 million (₹14.4 crore). PAT after share of profit from JVs was ₹103.2 million (₹10.3 crore), a 23.8% YoY increase.
The dental laboratory business grew by 23.5% YoY, with international operations showing a strong 37.4% growth. The Aligner Solutions business grew by 28.6% YoY. The company also noted that revenue does not include revenue from jointly controlled entities, Kids-e-Dental and IDBG AI Dent, as per Ind AS norms.
Rajesh Khakhar, Chairperson and Whole-Time Director, highlighted the strong start to FY27 and strategic initiatives. Sameer Merchant, Managing Director and CEO, attributed the performance to sales and operations teams' efforts and emphasized continued progress in digitalization and innovation.
What to do with a filing like this
Laxmi Dental Limited filed this with the NSE as a statutory disclosure, categorised under quarterly results. It is a primary document, not a recommendation, and the desk marks it medium impact: worth reading, rarely worth acting on by itself.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Laxmi Dental Limited. Read the original for the full detail.